This is compared to a loss from continuing operations of USD7.3m (loss of USD0.08 per diluted share) for the third quarter of 2008. A Total revenue of USD220.3m was generated in the third quarter of 2009, a hike of 31% as compared to USD168.4m in the third quarter of 2008. A Research and development costs went down 51% to USD11.3m in the third quarter of 2009, from USD23.2m in the corresponding period in 2008, primarily due to the company's new leveraged R&D model.
Valeant has raised its cash EPS target to between USD2.10 and USD2.20 in 2009, up from the prior guidance of USD1.90 to USD2.10.
Comments on this story may be sent to admin@m2.com

More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index